FOLH1 and neoplasm: In contrast, a first-in-human application of [177Lu]Lu-PSMA-ALB-56, a PSMA radioligand modified with a p-tolyl-butanoyl entity as an albumin binder, revealed similar salivary gland accumulation as [177Lu]Lu-PSMA-617 and, therefore, a favorable tumor-to-salivary gland dose ratio [15].